SGO 2020 orals and posters
Oral
Ostby SA, Roane B, Wall, JA Londono A, Goel N, Leath CA, Arend RC. How do uterine cancer NGS results impact patient outcomes? Society of Gynecologic Oncology Annual Meeting, Toronto, Canada, March 2020.
Davis AM, Londono AI, Cooper SJ, Arend RC. Metabolomic and transcriptomic response to neoadjuvant chemotherapy in HGSOC. Society of Gynecologic Oncology Annual Meeting, Toronto, Canada, March 2020.
Arend RC. Dkn-01 treated patients with recurrent epithelial endometrial (EEC) or ovarian (EOC) cancers which Harbor wnt activating mutations have longer progression free survival and improved clinical benefit. Society of Gynecologic Oncology Annual Meeting, Toronto, Canada, March 2020.
Arend Lab Poster
Arend R.C., Foxall M, Targeting glutaminase 1 to sensitize platinum-resistant BRCAwt ovarian cancer to PARP inhibitors. Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, Toronto, Canada, March 2020.
Wall JA, Davis AM, Beer H, Foxall M, Londono AI, McGwin G, Leath CA, Arend RC. Utilization of maintenance therapy for platinum-sensitive recurrent ovarian cancer. Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, Toronto, Canada, March 2020.
Goldsberry, W, Wall, J.A., Meza-Perez S, Katre AA, Londono A, Norian LA, Randall T, Arend RC. Inhibition of PORCN in a p53-/-Knockout Syngeneic Ovarian Cancer Model. Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, Toronto, Canada, March 2020.
Beer H, Foxall M, Wall JA, Londono AI, Bruton A, Roane BM, Goldsberry WN, Doo D, Leath CA, Huh WK, Arend RC. Improving gynecologic cancer clinical trial enrollment: A SWOT analysis. Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, Toronto, Canada, March 2020.
Foxall M, Londono A, Arend RC. Developing an epigenetic biomarker for early detection of ovarian cancer. Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, Toronto, Canada, March 2020.
Londono A, Arend RC. Concordance between targeted hotspot and full-exon next generation sequencing tests in ovarian and endometrial tumors. Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, Toronto, Canada, March 2020.
Kamal M, Londono A, Goldsberry W, Foxall M, Roane B, Katre A, Montgomery A, Arend R. Can DNA and RNA genomic signatures help predict risk of recurrence in high-intermediate risk endometrial cancer patients? Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, Toronto, Canada, March 2020.
Other UAB Faculty and Fellows
Boitano T, Straughn Jr. JM, . Enhanced recovery protocols decrease complication rates in all patients with a greater impact on the morbidly obese population. Society of Gynecologic Oncology Annual Meeting, Toronto, Canada, March 2020.
Rushton T, Doo D. Lymph node dissection for apparent stage I uterine carcinosarcoma provides no clear clinical benefit. Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, Toronto, Canada, March 2020.
Liang MI, Pisu M, Summerlin SS, Blanchard CT, Boitano TKL, Bhatia S, Huh WK. Interventions targeting work-related concerns and linkage to appropriate financial resources are needed for gynecologic cancer patients starting a new line of treatment. Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, Toronto, Canada, March 2020.
Ostby SA, Wall JA, Page M, Straughn, Jr JM, Smith HJ. The impact of code status simplification on end of life healthcare choices in gynecologic oncology. Society of Gynecologic Oncology Annual Meeting, Toronto, Canada, March 2020.
Wall JA, Lipking K, Smith HJ, Salter T, Bevis KS, Huh WK, Liang MI. Moderate/severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management. Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, Toronto, Canada, March 2020.
